Integra LifeSciences market cap is $5.7 b, and annual revenue was $1.37 b in FY 2020

Integra LifeSciences Gross profit (Q2, 2021)238.7 M

Integra LifeSciences Gross profit margin (Q2, 2021), %61.2%

Integra LifeSciences Net income (Q2, 2021)35.1 M

Integra LifeSciences EBIT (Q2, 2021)51.9 M

Integra LifeSciences Cash, 30-Jun-2021397.4 M

Integra LifeSciences EV6.2 B

Integra LifeSciences revenue was $1.37 b in FY, 2020

Integra LifeSciences revenue breakdown by business segment: 34.4% from Orthopedics and Tissue Technologies and 65.6% from Codman Specialty Surgical

Integra LifeSciences revenue breakdown by geographic segment: 5.6% from Rest of World, 10.4% from Asia Pacific, 13.0% from Europe and 71.0% from United States

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Revenue | 1.2b | 1.5b | 1.5b | 1.4b |

| 24% | 3% | ||

## Cost of goods sold | 435.5m | 571.5m | 564.7m | 520.8m |

## Gross profit | 752.7m | 900.9m | 952.9m | 851.0m |

| 63% | 61% | 63% | 62% |

## R&D expense | 63.5m | 78.0m | 79.6m | 77.4m |

## General and administrative expense | 624.1m | 690.7m | 687.6m | 594.5m |

## Operating expense total | 707.9m | 789.9m | 859.1m | 699.7m |

## Depreciation and amortization | 20.4m | 21.2m | 27.0m | 27.8m |

## EBIT | 44.8m | 111.0m | 93.8m | 151.4m |

| 4% | 8% | 6% | 11% |

## Interest expense | 35.0m | 64.7m | 54.0m | |

## Interest income | 255.0k | 2.8m | 10.8m | 9.3m |

## Pre tax profit | 11.4m | 57.4m | 60.1m | 93.5m |

## Income tax expense | (53.4m) | (3.4m) | 9.9m | (40.4m) |

## Net Income | 64.7m | 60.8m | 50.2m | 133.9m |

## EPS | 0.8 | 0.7 | 0.6 |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Cash | 174.9m | 138.8m | 198.9m | 470.2m |

## Accounts Receivable | 251.8m | 265.7m | 275.3m | 225.5m |

## Prepaid Expenses | 99.1m | 90.2m | 67.9m | 69.3m |

## Inventories | 296.3m | 280.3m | 316.1m | 310.1m |

## Current Assets | 822.1m | 775.1m | 858.2m | 1.2b |

## PP&E | 269.3m | 300.1m | 337.4m | 287.5m |

## Goodwill | 937.9m | 926.5m | 954.3m | 932.4m |

## Total Assets | 3.2b | 3.1b | 3.3b | 3.6b |

## Accounts Payable | 94.0m | 76.1m | 113.1m | 54.6m |

## Short-term debt | 60.0m | 22.5m | 57.3m | 91.6m |

## Current Liabilities | 348.9m | 262.6m | 331.3m | 401.0m |

## Long-term debt | 1.8b | 1.3b | 1.4b | 563.0m |

## Total Debt | 1.8b | 1.4b | 1.5b | 654.5m |

## Total Liabilities | 2.2b | 1.7b | 1.9b | 2.1b |

## Common Stock | 813.0k | 880.0k | 887.0k | 893.0k |

## Preferred Stock | ||||

## Additional Paid-in Capital | 821.8m | 1.2b | 1.2b | 1.3b |

## Retained Earnings | 285.2m | 348.4m | 398.6m | 532.3m |

## Total Equity | 962.3m | 1.4b | 1.4b | 1.5b |

## Debt to Equity Ratio | 1.9 x | 1 x | 1 x | |

## Debt to Assets Ratio | 0.6 x | 0.4 x | 0.4 x | |

## Financial Leverage | 3.3 x | 2.3 x | 2.3 x | 2.4 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Net Income | 64.7m | 60.8m | 50.2m | 133.9m |

## Depreciation and Amortization | 88.9m | 110.7m | 109.5m | 116.0m |

## Accounts Receivable | (89.7m) | (17.0m) | (9.4m) | 52.1m |

## Inventories | 99.0k | 8.3m | (43.3m) | (48.3m) |

## Accounts Payable | 95.3m | 3.6m | 14.7m | (57.5m) |

## Cash From Operating Activities | 114.5m | 199.7m | 231.4m | 203.8m |

## Purchases of PP&E | (43.5m) | (77.7m) | (69.5m) | (38.9m) |

## Cash From Investing Activities | (1.2b) | (49.7m) | (162.7m) | (68.1m) |

## Long-term Borrowings | (117.0m) | (660.0m) | (246.1m) | (441.0m) |

## Cash From Financing Activities | 1.2b | (180.9m) | (8.8m) | 121.6m |

## Net Change in Cash | 72.9m | (36.1m) | 60.1m | 271.3m |

USD | FY, 2017 |
---|---|

## Revenue/Employee | 270.1k |

## Debt/Equity | 1.9 x |

## Debt/Assets | 0.6 x |

## Financial Leverage | 3.3 x |